Publications by authors named "Licui Jiang"

Claim this Profile
B
B7-H3-Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors.
Licui Jiang, Fengtao You, Hai Wu, Changsong Qi, Shufen Xiang

Cancer Res· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD7 protein plays a crucial role in T cell infiltration in tumors.
Binjie Sheng, Kailu Zhang, Shuaiyu Tian, Renyuxue Ma, Zixuan Li, Licui Jiang

Heliyon· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nanobody-based anti-CD22-chimeric antigen receptor T cell immunotherapy exhibits improved remission against B-cell acute lymphoblastic leukemia.
Tingting Zhang, Tian Wang, Fengtao You, Zixuan Li, Dan Chen, Licui Jiang

Transpl Immunol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chimeric antigen receptor T cells derived from CD7 nanobody exhibit robust antitumor potential against CD7-positive malignancies.
Dan Chen, Fengtao You, Shufen Xiang, Yinyan Wang, Yafen Li, Licui Jiang

Am J Cancer Res· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MUC1-Tn-targeting chimeric antigen receptor-modified Vγ9Vδ2 T cells with enhanced antigen-specific anti-tumor activity.
Xiaochen Zhai, Fengtao You, Shufen Xiang, Licui Jiang, Dan Chen

Am J Cancer Res· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia.
Fengtao You, Yinyan Wang, Licui Jiang, Xuejun Zhu, Dan Chen

Am J Cancer Res· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.
Ying Chen, Fengtao You, Licui Jiang, Jialu Li, Xuejun Zhu

Oncotarget· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells.
Fengtao You, Licui Jiang, Bozhen Zhang, Qiang Lu, Qiao Zhou

Sci China Life Sci· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis